Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. infection resistant
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Infection Resistant Articles & Analysis

57 news found

Infection Control Resources to Identify Shigella and Other Pathogens in Puerto Rico

Infection Control Resources to Identify Shigella and Other Pathogens in Puerto Rico

The Centers for Disease Control and Prevention (CDC) reports there are an estimated 450,000 cases of shigellosis, an infection caused by Shigella bacteria, in the United States each year. Unfortunately, a growing number of these infections involve drug-resistant Shigella. The four species of Shigella listed by the CDC include: Shigella sonnei ...

ByCochrane & Associates, LLC


Profacgen Updates Its Antimicrobial Peptides Services to Drive Innovation in Antimicrobial Research

Profacgen Updates Its Antimicrobial Peptides Services to Drive Innovation in Antimicrobial Research

“Antimicrobial peptides have immense potential in addressing one of the most urgent challenges of our time—antibiotic resistance,” said Crystal, the Chief Marketing staff at Profacgen. ...

ByProfacgen


CD Formulation Leads the Way in Antiserum Preparation

CD Formulation Leads the Way in Antiserum Preparation

Antibacterial Serum Preparation Bacterial infections remain a significant concern globally, and the emergence of antibiotic-resistant strains has heightened this challenge. ...

ByCD Formulation


Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly finding new ways to avoid the effects of the antibiotics used to treat those infections. Vancomycin-resistant enterococci (VRE) is the name for the bacteria resistant to the antibiotic known as vancomycin. When the CDC released the 2019 Antibiotic ...

ByCochrane & Associates, LLC


XF-73 Nasal Phase 3 development plans finalised

XF-73 Nasal Phase 3 development plans finalised

XF-73 Nasal targeting peak sales potential of $1 billion in its major target markets Phase 3 patient recruitment could start in 2024 subject to completing an XF-73 Nasal partnering deal in 2023 XF-73 Nasal is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of post-surgical staphylococcal ...

ByDestiny Pharma plc


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

The objective of this research program is unique in that its goal is to prevent infections rather than treat them after they have already taken hold. This preventative approach will allow Lumen to develop an inexpensive, biologic drug cocktail against the most frequent, multi-drug resistant infecting pathogens. The therapeutic product would be ...

ByLumen Bioscience, Inc.


A project led by Vaxdyn receives funding from Next Generation EU Funds

A project led by Vaxdyn receives funding from Next Generation EU Funds

First, to raise specific immunity against one of the most important antibiotic-resistant bacteria in humans populations at hjgh-risk of development of antibiotic-resistant infections. And second, deliver to the porcine industry a vaccine to prevent infections of one of the most important causative agents of respiratory diseases ...

ByVaxdyn, S. L.


Infection Control Resources for Candida auris and Other Superbugs

Infection Control Resources for Candida auris and Other Superbugs

More than 2.8 million antibiotic-resistant infections occur in the U.S. each year and more than 35,000 people die as a result according to the CDC’s 2019 Antibiotic Resistance (AR) Threats Report. ...

ByCochrane & Associates, LLC


WHO calls for new innovations to tackle antimicrobial resistance crisis

WHO calls for new innovations to tackle antimicrobial resistance crisis

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection ...

ByOndine Biomedical Inc


OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

In this publication titled “Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalized patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomized controlled trial1,” the authors assessed the clinical utility and impact of the Unyvero panel in hospitalized adult patients with ...

ByOpGen, Inc.


OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

To help curb the global spread of antimicrobial resistance (AMR) pathogens, Ares Genetics is expanding its commercial offering of sequencing and analysis services aimed at clinical microbiologists and specialists in public health and infection prevention and control. ...

ByOpGen, Inc.


OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

(Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (Ares), which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), is expanding its strategic collaboration ...

ByOpGen, Inc.


How portable diagnostic readers are changing the future for patient care

How portable diagnostic readers are changing the future for patient care

A well known imaging side effect is exposure to radiation through an X Ray or CT scan potentially leading to the patient becoming unwell and having a low resistance to infection. Using a portable scanner increases patient safety by lowering the risk of adverse health effects. ...

ByAgPlus Diagnostics Ltd


Selux Diagnostics Announces Additional $50 Million in Series C Funding

Selux Diagnostics Announces Additional $50 Million in Series C Funding

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform. ...

BySelux Diagnostics, Inc.


MicrobioSeq Releases PCR-based Microbial Antibiotic Resistance Gene Analysis Service

MicrobioSeq Releases PCR-based Microbial Antibiotic Resistance Gene Analysis Service

The emergence and spread of drug-resistant pathogens that have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten to impair our ability to treat common infections. There is concern that the rapid global spread of multi-drug-resistant and ...

ByCD Genomics


Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer

Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that John Wilson has joined the company as Chief Commercial Officer. ...

BySelux Diagnostics, Inc.


Vaxdyn introduces its multi-pathogen vaccine candidate KapaVax at the World Vaccine Congress Europe

Vaxdyn introduces its multi-pathogen vaccine candidate KapaVax at the World Vaccine Congress Europe

The KapaVax candidate targets include three of the most worrisome antibiotic-resistant bacteria of the list of the WHO: Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, for which there are not available vaccines yet. The primary target population in need will be individuals affected by chronic lung problems in high risk of developing ...

ByVaxdyn, S. L.


Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform

Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has received a $2.8 million award from the U.S. ...

BySelux Diagnostics, Inc.


Specific Diagnostics Commences US Clinical Trials for FDA 510(k) Clearance of its Reveal Rapid AST System

Specific Diagnostics Commences US Clinical Trials for FDA 510(k) Clearance of its Reveal Rapid AST System

Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. ...

BySpecific Diagnostics


Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that its Next Generation 'Phenotyping' (NGP) platform has received Breakthrough Device Designation from the U.S. ...

BySelux Diagnostics, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT